ATE299890T1 - Inhibitoren von gamma-secretase - Google Patents

Inhibitoren von gamma-secretase

Info

Publication number
ATE299890T1
ATE299890T1 AT01907933T AT01907933T ATE299890T1 AT E299890 T1 ATE299890 T1 AT E299890T1 AT 01907933 T AT01907933 T AT 01907933T AT 01907933 T AT01907933 T AT 01907933T AT E299890 T1 ATE299890 T1 AT E299890T1
Authority
AT
Austria
Prior art keywords
inhibitors
gamma secretase
secretase
gamma
alzheimer
Prior art date
Application number
AT01907933T
Other languages
English (en)
Inventor
Pineiro Jose Luis Castro
Adrian Leonard Smith
Graeme Irvine Stevenson
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE299890T1 publication Critical patent/ATE299890T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT01907933T 2000-03-03 2001-02-28 Inhibitoren von gamma-secretase ATE299890T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0005251.4A GB0005251D0 (en) 2000-03-03 2000-03-03 Therapeutic compounds
PCT/GB2001/000855 WO2001066564A2 (en) 2000-03-03 2001-02-28 Gamma-secretase inhibitors

Publications (1)

Publication Number Publication Date
ATE299890T1 true ATE299890T1 (de) 2005-08-15

Family

ID=9886973

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01907933T ATE299890T1 (de) 2000-03-03 2001-02-28 Inhibitoren von gamma-secretase

Country Status (10)

Country Link
US (1) US7049296B2 (de)
EP (1) EP1263774B1 (de)
JP (1) JP2003525947A (de)
AT (1) ATE299890T1 (de)
AU (1) AU782884B2 (de)
CA (1) CA2401525A1 (de)
DE (1) DE60112055T2 (de)
ES (1) ES2243452T3 (de)
GB (1) GB0005251D0 (de)
WO (1) WO2001066564A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6696488B2 (en) 2000-08-11 2004-02-24 The Brigham And Women's Hospital, Inc. (Hydroxyethyl)ureas as inhibitors of alzheimer's β-amyloid production
ATE396174T1 (de) 2001-06-01 2008-06-15 Elan Pharm Inc Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
AU2002360508A1 (en) * 2001-12-06 2003-06-23 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamines
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
WO2005037316A1 (ja) * 2003-10-20 2005-04-28 Locomogene, Inc. セクレターゼ活性を抑制する方法
ES2383306T3 (es) 2004-02-03 2012-06-20 The Regents Of The University Of Michigan Composiciones para el tratamiento del cáncer de mama y de páncreas
AU2005209909B8 (en) * 2004-02-03 2009-01-15 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
US20060252073A1 (en) * 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
CA2617294A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii
JP5129149B2 (ja) 2005-10-31 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
US20080019961A1 (en) * 2006-02-21 2008-01-24 Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
EP2094836B1 (de) 2006-11-15 2016-06-08 Massachusetts Eye & Ear Infirmary Erzeugung von innerohrzellen
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
EP2106439B1 (de) 2007-01-24 2014-11-12 The Regents of the University of Michigan Zusammensetzungen und verfahren zur behandlung und diagnostizierung von pankreaskrebs
EP2117540A1 (de) 2007-03-01 2009-11-18 Probiodrug AG Neue verwendung von glutaminyl-cyclase-hemmern
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
WO2009035522A1 (en) * 2007-09-14 2009-03-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
EP2489656A1 (de) 2007-12-21 2012-08-22 Ligand Pharmaceuticals Inc. Selektive Androgenrezeptormodulatoren (SARMS) und ihre Verwendung
WO2009103072A2 (en) * 2008-02-14 2009-08-20 The Trustees Of The University Of Pennsylvania Erbb4 inhibitors and uses thereof in treatment of neuropsychiatric disorders
JP5809061B2 (ja) 2008-11-24 2015-11-10 マサチューセッツ・アイ・アンド・イア・インファーマリー 有毛細胞を産生するための経路
WO2011006144A1 (en) 2009-07-10 2011-01-13 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
JP2015527398A (ja) 2012-09-07 2015-09-17 マサチューセッツ アイ アンド イヤー インファーマリー 聴覚喪失治療
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
MX2015017103A (es) 2013-06-11 2016-11-07 Harvard College Celulas beta derivadas de células madre ( sc-beta ) y composiciones y métodos para generarlas.
US10441567B2 (en) 2014-01-17 2019-10-15 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
JP2017526641A (ja) 2014-07-11 2017-09-14 ジェネンテック， インコーポレイテッド Ｎｏｔｃｈ経路阻害
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
BR112018001480A2 (pt) 2015-07-24 2018-09-11 Oncotracker Inc moduladores de gama secretase para o tratamento de disfunção do sistema imunológico
WO2017096233A1 (en) 2015-12-04 2017-06-08 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
CA3013038A1 (en) 2016-01-29 2017-08-03 Massachusetts Eye And Ear Infirmary Expansion and differentiation of inner ear supporting cells and methods of use thereof
AU2017268078B2 (en) 2016-05-16 2023-03-02 The General Hospital Corporation Human airway stem cells in lung epithelial engineering
IL267253B2 (en) 2016-12-16 2023-04-01 Pipeline Therapeutics Inc Methods for treating cochlear synaptopathy
US11845803B2 (en) 2017-02-17 2023-12-19 Fred Hutchinson Cancer Center Combination therapies for treatment of BCMA-related cancers and autoimmune disorders
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
EP3833365A4 (de) 2018-08-10 2022-05-11 Vertex Pharmaceuticals Incorporated Aus stammzellen gewonnene inseldifferenzierung
KR20230005163A (ko) 2020-03-26 2023-01-09 씨젠 인크. 다발성 골수종 치료 방법
IL311636A (en) 2021-11-01 2024-05-01 Vertex Pharma Differentiation of stem cell-derived pancreatic islets

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU9301446D0 (en) * 1990-11-19 1993-11-29 Monsanto Co Inhibitors or fetrovirus protease
WO2001053255A1 (en) * 2000-01-24 2001-07-26 Merck Sharp & Dohme Limited Gamma-secretase inhibitors

Also Published As

Publication number Publication date
EP1263774B1 (de) 2005-07-20
ES2243452T3 (es) 2005-12-01
AU782884B2 (en) 2005-09-08
DE60112055D1 (de) 2005-08-25
EP1263774A2 (de) 2002-12-11
DE60112055T2 (de) 2006-04-27
AU3579901A (en) 2001-09-17
WO2001066564A3 (en) 2002-01-03
US7049296B2 (en) 2006-05-23
WO2001066564A2 (en) 2001-09-13
JP2003525947A (ja) 2003-09-02
CA2401525A1 (en) 2001-09-13
US20030055005A1 (en) 2003-03-20
GB0005251D0 (en) 2000-04-26

Similar Documents

Publication Publication Date Title
DE60112055D1 (de) Inhibitoren von gamma-secretase
ATE401314T1 (de) Benzodiazepin-derivate als gamma-secretase inhibitoren
ATE346039T1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
ATE386028T1 (de) Zyklohexylsulfone als gamma-sekretase-inhibitoren
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
ATE464287T1 (de) Cyclohexyl-sulphone als gamma-sekretase- inhibitoren
DE60237725D1 (de) Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit
GB0225474D0 (en) Therapeutic agents
ATE368031T1 (de) Neue gamma secretase inhibitoren
DE60144064D1 (de) Sulfone, die die aktivität von gamma-secretase modulieren
TR200000059T2 (tr) Piridin türevleri
BR9205811A (pt) Derivados heterociclicos de aminas ciclicas
ATE427300T1 (de) Heterocyclisch substituierte amide als calpainhemmer
ATE444293T1 (de) Cyclische sulfamide zur inhibierung von gamma- sekretase
DE60112942D1 (de) Verbindungen zur behandlung der alzheimerischen krankheit
AP2001002318A0 (en) Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
DE60121461D1 (de) Kondensierte pyridoindolderivate
DE59914814D1 (de) Heterozyklische substituierte amide, deren herstellung und anwendung
ATE316962T1 (de) Pyrimidin-derivate als selective inhibitoren von cox-2
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
DE60013486D1 (de) Verbindungen
DE60112960D1 (de) Kondensierte pyridoindolderivate
ATE274513T1 (de) Verbindungen und verfahren zur behandlung von schmerz

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties